Managing Treatment-Resistant Depression: Road to Novel Therapeutics
Editat de Joao L. de Quevedo, Patricio Riva-Posse, William V. Boboen Limba Engleză Paperback – 3 apr 2022
- Defines Treatment-Resistant Depression and Staging Treatment Intensity
- Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions
- Discusses the use of Ketamine and Esketamine for treatment-resistant depression
Preț: 1138.12 lei
Preț vechi: 1491.62 lei
-24% Nou
Puncte Express: 1707
Preț estimativ în valută:
217.81€ • 229.13$ • 181.74£
217.81€ • 229.13$ • 181.74£
Carte tipărită la comandă
Livrare economică 02-16 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128240670
ISBN-10: 0128240679
Pagini: 612
Ilustrații: 35 illustrations (10 in full color)
Dimensiuni: 216 x 276 mm
Editura: ELSEVIER SCIENCE
ISBN-10: 0128240679
Pagini: 612
Ilustrații: 35 illustrations (10 in full color)
Dimensiuni: 216 x 276 mm
Editura: ELSEVIER SCIENCE
Cuprins
1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity
2. Clinical and epidemiological predictors of treatment-resistant depression
3. The economic burden of treatment-resistant depression: Cost-of-illness perspective
4. The neurobiology of treatmentresistant depression
5. Modeling treatment-resistant depression in the preclinical setting
6. Treatment algorithms for treatment-resistant depression
7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
8. Tricyclic antidepressants for treatment-resistant depression
9. Monoamine oxidase inhibitors for treatment-resistant depression
10. Switching antidepressants in patients with treatment-resistant depression
11. Adjunctive strategies for treatment-resistant depression
12. Combining antidepressants to address treatment-resistant depression
13. Ketamine/esketamine for treatment-resistant depression
14. Psychedelic agents for treatmentresistant depression
15. Inflammation and treatment resistance: Mechanisms and treatment implications
16. Opioid agents for treatmentresistant depression
17. Transcranial magnetic stimulation for treatment-resistant depression
18. tDCS for treatment-resistant depression
19. ECT for treatment-resistant depression
20. MST for treatment-resistant depression
21. VNS for treatment-resistant depression
22. Deep brain stimulation for treatment-resistant depression
23. Other neurosurgical interventions for treatment-resistant depression
24. Treatment-resistant psychotic depression
25. Evidence-based psychotherapy for treatment-resistant depression
26. Treatment-resistant bipolar depression
27. Treatment-resistant depression in child and adolescents
28. Treatment-resistant depression in geriatrics
29. Identification and management of anxious depression in patients with treatment-resistant depression
30. Managing treatment-resistant depression with comorbid personality disorders
31. Managing treatment-resistant depression with comorbid substance use disorders
32. Managing treatment-resistant depression in the setting of chronic pain
33. Inhaled gases for treatmentresistant major depression
34. Drugs under investigation for treatment-resistant depression
35. Chronotherapeutics for treatmentresistant depression
36. Managing treatment resistant depression in primary care settings
37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
38. Lifestyle interventions for treatment-resistant depression
39. Managing the risk of suicide in people with treatment-resistant depression
40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression
2. Clinical and epidemiological predictors of treatment-resistant depression
3. The economic burden of treatment-resistant depression: Cost-of-illness perspective
4. The neurobiology of treatmentresistant depression
5. Modeling treatment-resistant depression in the preclinical setting
6. Treatment algorithms for treatment-resistant depression
7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
8. Tricyclic antidepressants for treatment-resistant depression
9. Monoamine oxidase inhibitors for treatment-resistant depression
10. Switching antidepressants in patients with treatment-resistant depression
11. Adjunctive strategies for treatment-resistant depression
12. Combining antidepressants to address treatment-resistant depression
13. Ketamine/esketamine for treatment-resistant depression
14. Psychedelic agents for treatmentresistant depression
15. Inflammation and treatment resistance: Mechanisms and treatment implications
16. Opioid agents for treatmentresistant depression
17. Transcranial magnetic stimulation for treatment-resistant depression
18. tDCS for treatment-resistant depression
19. ECT for treatment-resistant depression
20. MST for treatment-resistant depression
21. VNS for treatment-resistant depression
22. Deep brain stimulation for treatment-resistant depression
23. Other neurosurgical interventions for treatment-resistant depression
24. Treatment-resistant psychotic depression
25. Evidence-based psychotherapy for treatment-resistant depression
26. Treatment-resistant bipolar depression
27. Treatment-resistant depression in child and adolescents
28. Treatment-resistant depression in geriatrics
29. Identification and management of anxious depression in patients with treatment-resistant depression
30. Managing treatment-resistant depression with comorbid personality disorders
31. Managing treatment-resistant depression with comorbid substance use disorders
32. Managing treatment-resistant depression in the setting of chronic pain
33. Inhaled gases for treatmentresistant major depression
34. Drugs under investigation for treatment-resistant depression
35. Chronotherapeutics for treatmentresistant depression
36. Managing treatment resistant depression in primary care settings
37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
38. Lifestyle interventions for treatment-resistant depression
39. Managing the risk of suicide in people with treatment-resistant depression
40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression